Advertisement

Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Organisation › Details

InflaRx (Group)

InflaRx is a biopharmaceutical company focusing on the development of new therapeutics controlling the inflammatory response based on its proprietary technology.. InflaRx has developed a pipeline of first-in-class antibodies directed against the terminal complement component C5a. While IFX-1 focuses on the acute care space, its product candidates, IFX-2 and IFX-3, are being developed in chronic inflammatory disease indications. InflaRx was founded in 2007 and is headquartered in Jena, Germany, with long standing research collaborations in the US and China. The team consists of renowned experts in complement research and clinical acute care. InflaRx is privately owned and financed by bm-t Beteiligungsmanagement Thüringen Gmbh, KfW banking group and various international family offices. *

 

Period Start 2007-01-01 established
Products Industry anti-inflammatory drug
  Industry 2 IFX-1 (InflaRx)
Persons Person Riedemann, Niels C. (InflaRx 200803 Managing Director + founder)
  Person 2 Christ, Arnd (Immatics 202010– CFO before InflaRx + Proteros + MediGene + NovImmune + Probiodrug + Hoechst)
     
Region Region Jena
  Country Germany
  Street 2 Winzerlaer Str.
  City 07745 Jena
    Address record changed: 2020-12-12
     
Basic data Employees n. a.
  Currency EUR
  Profit -53,254,817 (2019-12-31)
  Cash 115,485,147 (2019-12-31)
     
    * Document for �About Section�: 
     
   
Record changed: 2020-12-12

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for InflaRx (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px




» top